Description

Scope of the Report:

The global Phosphodiesterase Type 5 (PDE5) Inhibitor market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Phosphodiesterase Type 5 (PDE5) Inhibitor.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Phosphodiesterase Type 5 (PDE5) Inhibitor market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Phosphodiesterase Type 5 (PDE5) Inhibitor market by product type and applications/end industries.

Market Segment by Companies, this report covers

Eli Lilly

AstraZeneca

Novartis AG

Pfizer

Roche

Bayer

SK Chemicals

GlaxoSmithKline plc

Merck

BaiYunShan General Factory

Vectura Group

Teva Pharma

Seoul Pharma

Dong-A ST

Metuchen Pharma

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Sildenafil

Tadalafil

Avanafil

Vardenafil

Market Segment by Applications, can be divided into

Hospital

Retail Pharmacy

Online Pharmacies

Other

Table of Contents

1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Overview

1.1 Product Overview and Scope of Phosphodiesterase Type 5 (PDE5) Inhibitor

1.2 Classification of Phosphodiesterase Type 5 (PDE5) Inhibitor by Types

1.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Comparison by Types (2019-2024)

1.2.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Types in 2018

1.2.3 Sildenafil

1.2.4 Tadalafil

1.2.5 Avanafil

1.2.6 Vardenafil

1.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market by Application

1.3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Online Pharmacies

1.3.5 Other

1.4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market by Regions

1.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Phosphodiesterase Type 5 (PDE5) Inhibitor Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Phosphodiesterase Type 5 (PDE5) Inhibitor Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Phosphodiesterase Type 5 (PDE5) Inhibitor Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Phosphodiesterase Type 5 (PDE5) Inhibitor Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Phosphodiesterase Type 5 (PDE5) Inhibitor Status and Prospect (2014-2024)

1.5 Global Market Size of Phosphodiesterase Type 5 (PDE5) Inhibitor (2014-2024)

2 Company Profiles

2.1 Eli Lilly

2.1.1 Business Overview

2.1.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.2 AstraZeneca

2.2.1 Business Overview

2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.3 Novartis AG

2.3.1 Business Overview

2.3.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.4 Pfizer

2.4.1 Business Overview

2.4.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.5 Roche

2.5.1 Business Overview

2.5.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.6 Bayer

2.6.1 Business Overview

2.6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.7 SK Chemicals

2.7.1 Business Overview

2.7.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.8 GlaxoSmithKline plc

2.8.1 Business Overview

2.8.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.9 Merck

2.9.1 Business Overview

2.9.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.10 BaiYunShan General Factory

2.10.1 Business Overview

2.10.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.11 Vectura Group

2.11.1 Business Overview

2.11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.12 Teva Pharma

2.12.1 Business Overview

2.12.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.13 Seoul Pharma

2.13.1 Business Overview

2.13.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.14 Dong-A ST

2.14.1 Business Overview

2.14.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.14.2.1 Product A

2.14.2.2 Product B

2.14.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

2.15 Metuchen Pharma

2.15.1 Business Overview

2.15.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Type and Applications

2.15.2.1 Product A

2.15.2.2 Product B

2.15.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2017-2018)

3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Competition, by Players

3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Phosphodiesterase Type 5 (PDE5) Inhibitor Players Market Share

3.2.2 Top 10 Phosphodiesterase Type 5 (PDE5) Inhibitor Players Market Share

3.3 Market Competition Trend

4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions

4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Regions

4.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

4.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

4.5 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

5 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries

5.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries (2014-2019)

5.2 USA Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

5.3 Canada Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

5.4 Mexico Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

6 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries

6.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries (2014-2019)

6.2 Germany Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

6.3 UK Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

6.4 France Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

6.5 Russia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

6.6 Italy Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries

7.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries (2014-2019)

7.2 China Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

7.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

7.4 Korea Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

7.5 India Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

8 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries

8.1 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries (2014-2019)

8.2 Brazil Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

8.3 Argentina Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

8.4 Colombia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Phosphodiesterase Type 5 (PDE5) Inhibitor by Countries

9.1 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Countries (2014-2019)

9.2 Saudi Arabia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

9.3 UAE Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

9.4 Egypt Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

9.5 Nigeria Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

9.6 South Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2014-2019)

10 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment by Type

10.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Type (2014-2019)

10.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Type (2019-2024)

10.3 Sildenafil Revenue Growth Rate (2014-2024)

10.4 Tadalafil Revenue Growth Rate (2014-2024)

10.5 Avanafil Revenue Growth Rate (2014-2024)

10.6 Vardenafil Revenue Growth Rate (2014-2024)

11 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Segment by Application

11.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application (2014-2019)

11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Application (2019-2024)

11.3 Hospital Revenue Growth (2014-2019)

11.4 Retail Pharmacy Revenue Growth (2014-2019)

11.5 Online Pharmacies Revenue Growth (2014-2019)

11.6 Other Revenue Growth (2014-2019)

12 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Forecast (2019-2024)

12.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Forecast (2019-2024)

12.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Regions (2019-2024)

12.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Forecast (2019-2024)

12.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Forecast (2019-2024)

12.6 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Phosphodiesterase Type 5 (PDE5) Inhibitor Picture

Table Product Specifications of Phosphodiesterase Type 5 (PDE5) Inhibitor

Table Global Phosphodiesterase Type 5 (PD